ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 660 DKK | +5.10% |
|
+4.27% | +76.85% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
Presenter SpeechMartin Nicklasson (Executives)On behalf of the Board of Directors and Executiv...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
660
DKK
Average target price
782
DKK
Spread / Average Target
+18.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +76.85% | 5.65B | |
| +10.44% | 106B | |
| +0.82% | 104B | |
| +6.72% | 23.25B | |
| -13.89% | 22.5B | |
| -6.64% | 18.7B | |
| -37.26% | 17.95B | |
| -10.98% | 16.99B | |
| +8.67% | 14.26B | |
| +41.08% | 12.76B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Transcript : Zealand Pharma A/S - Shareholder/Analyst Call